C9098 HCPCS Level II code: Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose…
CMS terminated C9098: its last date of service was Sep 30, 2022. It stays here for looking up older claims; newer services need a current code.
Official description
C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short description: Ciltacabtagene car pos t
HCPCS · United States
Medicare details
The indicators CMS publishes with C9098 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Statute
- Type of service
- Medical care
- BETOS category
- Chemotherapy
- Added
- Jul 1, 2022
- Terminated after
- Sep 30, 2022
Where C9098 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9098Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9098 still valid?
No. CMS terminated C9098; its last date of service was Sep 30, 2022. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9098?
CMS lists C9098’s Medicare coverage as “Carrier judgment” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9098
All C codesC9092Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mgC9093Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mgC9094Inj, sutimlimab-jome, 10 mgC9095Inj, tebentafusp-tebn, 1 mcgC9096Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramC9097Inj, faricimab-svoa, 0.1 mgC9101Injection, oliceridine, 0.1 mgC9113Injection, pantoprazole sodium, per vialC9121Injection, argatroban, per 5 mgC9122Mometasone furoate sinus implant, 10 micrograms (sinuva)C9132Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activityC9133Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.